NEW YORK, Oct. 11 – Luminex said on Thursday that a surprising surge in sales during the third-quarter will help the company report greater-than-expected revenues and a leaner loss than Wall Street had forecast for the period.

The Austin, Tex.-based bead-array developer said in a statement that revenues for the quarter ended Sept. 30 would be about $6.2 million, exceeding the $6.1 million offered by an analysts’ consensus estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.